NCT01540526View on ClinicalTrials.gov

Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

December 31, 2014

Conditions
Solid MalignanciesMetastatic Castrate-resistant Prostate Cancer
Interventions
DRUG

axitinib

7 mg PO BID days 1-14 in 21 day cycles.

Trial Locations (1)

53792

University of Wisconsin Carbone Cancer Center, Madison

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Wisconsin, Madison

OTHER

NCT01540526 - Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib | Biotech Hunter | Biotech Hunter